Abstract | OBJECTIVES: METHODS: A total of 60 patients (39 men, 21 women, mean age 65 +/- 11 years) were given disopyramide (300 mg/day) after electrical and pharmacological cardioversion based on American Heart Association Task Force on Practice Guidelines. The patients were divided into two types based on the duration of atrial fibrillation: conversion within 48 hr (group A, n = 35) and more than 48 hr (group B, n = 25) after the episode. Mean follow-up period was 47.1 +/- 28.7 months. RESULTS: Patient characteristics showed no statistically significant difference between groups A and B. The actuarial rates of maintenance of sinus rhythm at 1, 3, 6, 12, 18 and 24 months were 88.6%, 77.1%, 57.1%, 48.6%, 42.9% and 37.1%, respectively, in group A, and 72.0%, 44.0%, 28.0%, 16.0%, 12.0% and 8.0%, respectively, in group B. There was a significant difference in the rate at 24 months between groups A and B (p < 0.05). The periods for maintenance of sinus rhythm in groups A and B were 20.9 +/- 3.9 and 6.7 +/- 2.1 months, respectively, with a significant difference between groups A and B (p < 0.01). CONCLUSIONS: The efficacy of disopyramide in preventing the recurrence of atrial fibrillation varies with the duration of the previous episode. These results demonstrate that it is important to convert to normal sinus rhythm earlier to prevent the recurrence of atrial fibrillation in the long term.
|
Authors | Takashi Komatsu, Kunihiko Yomogida, Shin Nakamura, Osamu Suzuki, Daisuke Horiuchi, Kunihiko Kameda, Hirofumi Tomita, Naoki Abe, Shingen Owada, Koichi Oikawa, Ken Okumura |
Journal | Journal of cardiology
(J Cardiol)
Vol. 42
Issue 3
Pg. 111-7
(Sep 2003)
ISSN: 0914-5087 [Print] Netherlands |
PMID | 14526660
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Disopyramide
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(therapeutic use)
- Arrhythmias, Cardiac
(therapy)
- Atrial Fibrillation
(complications, prevention & control, therapy)
- Disopyramide
(therapeutic use)
- Electric Countershock
- Female
- Follow-Up Studies
- Humans
- Male
- Secondary Prevention
- Time Factors
|